US 11,932,846 B2
Chloramphenicol resistant split protein and uses thereof
Gali Prag, Tel-Aviv (IL)
Assigned to Technology Innovation Momentum Fund (Israel) Limited Partnership, Tel-Aviv (IL)
Appl. No. 16/634,898
Filed by Technology Innovation Momentum Fund (Israel) Limited Partnership, Tel-Aviv (IL)
PCT Filed Aug. 8, 2018, PCT No. PCT/IL2018/050880
§ 371(c)(1), (2) Date Jan. 29, 2020,
PCT Pub. No. WO2019/030759, PCT Pub. Date Feb. 14, 2019.
Claims priority of provisional application 62/542,333, filed on Aug. 8, 2017.
Prior Publication US 2020/0385706 A1, Dec. 10, 2020
Int. Cl. C12N 15/10 (2006.01); C12N 15/03 (2006.01); C12Q 1/02 (2006.01); C12Q 1/48 (2006.01)
CPC C12N 15/1055 (2013.01) [C12N 15/03 (2013.01); C12Q 1/025 (2013.01); C12Q 1/48 (2013.01); C12Y 203/01028 (2013.01); G01N 2333/91062 (2013.01); G01N 2500/02 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A construct system comprising:
(i) a first nucleic acid construct comprising a first polynucleotide having a nucleic acid sequence that encodes a N-terminal fragment of chloramphenicol acetyl transferase (CAT), said N-terminal fragment comprising a first portion of the catalytic active site of said CAT, said N-terminal fragment being devoid of acetylating activity; and
(ii) a second nucleic acid construct comprising a second polynucleotide having a nucleic acid sequence that encodes a C terminal fragment of said CAT, said C-terminal fragment comprising a second portion of the catalytic active site of said CAT, said C-terminal fragment being devoid of acetylating activity; and
wherein said N-terminal fragment is capable of associating with said C-terminal fragment to generate an active CAT that is capable of acetylating chloramphenicol,
wherein said N terminal fragment consists of the amino acid sequence as set forth in SEQ ID NO: 2 or 6; and/or
said C-terminal fragment consists of the amino acid sequence as set forth in SEQ ID NOs: 3 or 7.